Tuning T‐Cell Receptor Affinity to Optimize Clinical Risk‐Benefit When Targeting Alpha‐Fetoprotein–Positive Liver Cancer

Patients with hepatocellular carcinoma (HCC) have a poor prognosis and limited therapeutic options. Alpha‐fetoprotein (AFP) is often expressed at high levels in HCC and is an established clinical biomarker of the disease. Expression of AFP in nonmalignant liver can occur, particularly in a subset of...

Descripción completa

Detalles Bibliográficos
Autores principales: Docta, Roslin Y., Ferronha, Tiago, Sanderson, Joseph P., Weissensteiner, Thomas, Pope, George R., Bennett, Alan D., Pumphrey, Nicholas J., Ferjentsik, Zoltan, Quinn, Laura L., Wiedermann, Guy E., Anderson, Victoria E., Saini, Manoj, Maroto, Miguel, Norry, Elliot, Gerry, Andrew B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593660/
https://www.ncbi.nlm.nih.gov/pubmed/30561769
http://dx.doi.org/10.1002/hep.30477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593660/
https://www.ncbi.nlm.nih.gov/pubmed/30561769
http://dx.doi.org/10.1002/hep.30477

Ejemplares similares